98%
921
2 minutes
20
Although there is ongoing debate over the need for substantial increases in pre-exposure prophylaxis (PrEP) use when antiretroviral treatment confers the dual benefits of reducing HIV-related morbidity and mortality and the risk of HIV transmission, no studies to date have quantified the potential added benefits of PrEP use and changes in its efficiency in the context of high treatment engagement across multiple US subpopulations. We used a previously published agent-based model to simulate HIV transmission in a dynamic network of Black/African American and White men who have sex with men (MSM) in Atlanta, Georgia (2015-2024) to understand how reductions in HIV incidence attributable to varying levels of PrEP use change when United Nations Joint Programme on HIV/AIDS (UNAIDS) "90-90-90" goals for HIV treatment are achieved and maintained. Even at achievement of "90-90-90" goals, 75% PrEP coverage further reduced incidence by 67.9% and 74.2% to 1.53 [simulation interval (SI): 1.39-1.70] and 0.355 (SI: 0.316-0.391) per 100 person-years for Black/African American and White MSM, respectively, compared with the same scenario with no PrEP use. Increasing PrEP coverage from 15% to 75% under "90-90-90" goals only increased the number of person-years of PrEP use per infection averted by 8.1% and 10.5% to 26.7 (SI: 25.6-28.0) and 73.3 (SI: 70.6-75.7) among Black/African American MSM and White MSM, respectively. Even with high treatment engagement, substantial expansion of PrEP use contributes to meaningful decreases in HIV incidence among MSM with minimal changes in efficiency.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757534 | PMC |
http://dx.doi.org/10.1089/apc.2020.0151 | DOI Listing |
JHEP Rep
October 2025
HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited.
View Article and Find Full Text PDFOpen Forum Infect Dis
September 2025
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Accurate point-of-care tools are needed to detect early nonadherence to daily HIV regimens and support timely transitions to long-acting options. Emerging evidence suggests that females may require higher adherence than males to achieve equivalent protection. Our next-generation urine tenofovir assay showed high accuracy across sexes but lower urine drug levels among female participants.
View Article and Find Full Text PDFHealth Policy Plan
September 2025
Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.
The COVID-19 pandemic had significant widespread financial impacts, resulting in decreased household income, increased unemployment, and disrupted health services. Despite the higher prevalence of infections of tuberculosis (TB) and human immunodeficiency virus (HIV) in poorer populations, research on the financial challenges faced by these populations during the pandemic is still limited. Indonesia recorded the highest COVID-19 cases in Southeast Asia (6,815,156) while contending with the dual burden of HIV and TB.
View Article and Find Full Text PDFPLoS One
September 2025
School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
Background: Despite advances in HIV care, viral load suppression (VLS) among adolescents living with HIV (ALHIV) in Uganda continue to lag behind that of adults, even with the introduction of dolutegravir (DTG)-based regimens, the Youth and Adolescent Peer Supporter (YAPS) model, and community-based approaches. Understanding factors associated with HIV viral load non-suppression in this population is critical to inform HIV treatment policy. This study assessed the prevalence and predictors of viral load non-suppression among ALHIV aged 10-19 years on DTG-based ART in Soroti City, Uganda.
View Article and Find Full Text PDFPLoS Med
September 2025
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.
Background: Oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence. For men who have sex with men, a dosing study in the United States (US) population defined clinically meaningful tenofovir diphosphate (TFV-DP) thresholds in dried blood spots (DBS) based on the rounded 25th percentile for 2, 4, and 7 doses/week as 350, 700, and 1,250 fmol/punch. However, divergent efficacy results in the first generation randomized clinical trials of F/TDF PrEP among African women led to several hypotheses to question whether the pharmacology and adherence requirement for oral F/TDF PrEP may be different in cisgender women compared to what is already established for men.
View Article and Find Full Text PDF